RPG Life Sciences to acquire Raghava Life Sciences' API business

RPG Life Sciences announced the acquisition of Raghava Life Sciences' active pharmaceutical ingredients (API) and intermediates division in an all-cash transaction valued at ₹135 crore. The deal represents a strategic move by the Mumbai-based pharmaceutical manufacturer to strengthen its portfolio and production capacity in the competitive generics sector.

The acquisition encompasses Raghava Life Sciences' established API and intermediates business, which serves multiple clients across the pharmaceutical industry. The transaction is expected to provide RPG Life Sciences with additional manufacturing assets and technical expertise to meet growing demand from its customer base.

RPG Life Sciences, a subsidiary of RPG Enterprises, has been actively expanding its presence in the pharmaceutical manufacturing space. The company produces a range of active ingredients and finished pharmaceutical products for domestic and international markets. This acquisition aligns with the company's strategy to consolidate operations and enhance its competitive positioning in the API segment.

The transaction is subject to customary closing conditions and regulatory approvals. Industry analysts view the deal as part of a broader consolidation trend in India's pharmaceutical manufacturing sector, where companies are seeking to optimize production capabilities and achieve economies of scale amid increasing competition.